O9 Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis

Post time 3 day(s) ago

journal：Oral presentations

Authors：David Jones; Vaclav Hejda; Alexandre Louvet; Antonio Civitarese; Lynda Szczech; Heng Zou; Frederik Nevens

Published date：2023-9-

DOI：10.1136/gutjnl-2023-basl.9

PDF link：https://syndication.highwire.org ... /gutjnl-2023-BASL.9

Article link：http://dx.doi.org/10.1136/gutjnl-2023-basl.9

Article Source：BMJ Publishing Group Ltd and British Society of Gastroenterology。

Remark：

Post time The day before yesterday 19:02

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[BMJ] O9 Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis

Same Category

Latest Reply

Announcement

Enthusiastic users today

[BMJ] O9 Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis Copy

Same Category

Latest Reply

Announcement

Enthusiastic users today

[BMJ] O9 Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis